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Decreased renal function is often a complication of hypertension. Although it has been suggested that the response
of the kidney to hypertension has an underlying genetic component, there is limited information suggesting that
specific genetic regions or candidate genes contribute to the variability in creatinine clearance, a commonly used
measure of kidney function. As part of the Hypertension Genetic Epidemiology Network (HyperGEN) study,
creatinine clearance measurements were assessed in a large biracial sample of hypertensive siblings (466 African
American subjects and 634 white subjects in 215 and 265 sibships, respectively). All participants were hypertensive
before the age of 60 years, and the mean age of the siblings was 52 years among the African American subjects
and 61 years among the white subjects. Two residual models were created for creatinine clearance: a minimally
adjusted model (which included age and age2) and a fully adjusted model (which included age, age2, lean body
mass, pulse rate, pulse pressure, hormone-replacement therapy, educational status, and physical activity). Stan-
dardized residuals were calculated separately for men and women in both racial groups. The heritability of the
residual creatinine clearance was 17% and 18% among the African American and white subjects, respectively. We
conducted multipoint variance components linkage analysis using GENEHUNTER2 and 387 anonymous markers
(Cooperative Human Linkage Center screening set 8). The best evidence for linkage in African American subjects
was found on chromosome 3 (LODp 3.61 at 214.6 cM, 3q27) with the fully adjusted model, and the best evidence
in white subjects was found on chromosome 3 (LOD p 3.36 at 115.1 cM) with the minimally adjusted model.
Positional candidate genes that are contained in and around the region on chromosome 3 (214.6 cM) that may
contribute to renal function include enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase (EHHADH) and apo-
lipoprotein D (ApoD). These findings suggest there may be genetic regions related to the variability of creatinine
clearance among hypertensive individuals.
Introduction
Although there is conflicting evidence on the role of the
kidney in initiating hypertension in humans (Woolfson
and de Wardener 1996), the kidney eventually becomes
a target of the increased arterial pressure (Lindeman et
al. 1984; Walker et al. 1992). Primary hypertension, that
is, hypertension without known cause, is the most com-
mon cause of end-stage renal disease (ESRD) in the
United States (Woolfson and de Wardener 1996). It has
been reported that the rate of chronic renal failure may
be as high as 20%–30% among individuals with un-
treated primary hypertension (Brown and Whithworth
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1992), and there is strong evidence to suggest that, al-
though treatment for hypertension has reduced the rates
of myocardial infarction and stroke, it is not reducing
the rate of ESRD (Seedat 1999; Jaimes et al. 1996). The
precise mechanism of renal damage due to hypertension
is unclear, but it appears that either a thickening of the
glomerular vascular structure or a hyalinization and scle-
rosis of the walls of the preglomerular (afferent) arte-
rioles may decrease the blood supply to the nephron,
thereby leading to a decreased ability to concentrate
urine (Porth 1994). The decreased ability to concentrate
urine results in a decreased glomerular filtration rate
(GFR) and, eventually, in ESRD. Hemodynamic alter-
ations in the kidney are also reported to occur before
the onset of hypertension (Lebel et al. 1991). Structural
changes in the arteries in the kidney disturb the normal-
pressure natriuresis, thereby raising blood pressure (BP).
Therefore, renal disease is complex and may result from
hypertension and/or lead to its development.
It has been suggested that some persons may be es-
pecially susceptible to renal damage due to hypertension
DeWan et al.: Genome Scan for Renal Function 137
(Cusi et al. 1993). There is evidence of a familial as-
sociation of ESRD due to hypertension (Ferguson et al.
1988), suggesting a genetic component to this increased
susceptibility although there is no evidence for linked
chromosomal regions or candidate genes in humans.
However, there is evidence for linkage, on chromosome
1, to hypertension-induced renal damage in rats that is
consistent across strains of rats (Brown et al. 1996; St.
Lezin et al. 1999).
There is mounting evidence that the rate of kidney
disease due to hypertension is far greater in African
Americans than in whites (Rostand et al. 1982; Tierney
et al. 1989; Blythe and Maddux 1991). In 1987, the
rate of ESRD in hypertensive African Americans was
6.6 times that in hypertensive whites and was even
higher when individuals 155 years old were compared
(Blythe andMaddux 1991). Rostand et al. (1982) found
the rate of hypertensive renal disease among the African
American population of an urban Alabama county to
be 17 times higher than that among the white popu-
lation of the same county. This may result, in part, from
socioeconomic factors, such as less-frequent treatment
of hypertension among African Americans, but it may
also represent a true difference in the renal response to
elevated BP (Campese 1996), suggesting a physiological
basis for ethnic differences in renal disease. The Mul-
tiple Risk Factor Intervention Trial Research Group
found that renal function improved in response to BP
control in white men but not African American men
(Walker et al. 1992), again suggesting that racial groups
differ in their response to increasing BP. Gene frequen-
cies influencing the response of the kidney to hyperten-
sion may differ greatly between ethnic groups and may
provide an explanation for the observed excess of kid-
ney disease in African Americans.
The present article reports the results from a ge-
nomewide scan to detect genetic regions influencing the
variability of creatinine clearance, a measure of kidney
function, among hypertensive siblings without renal
failure. The objectives are to determine whether such
linkages exist and whether the genomic regions linked
to creatinine clearance are similar in African Americans
and whites.
Methods
Population
Subjects in this study included 480 sibships of two to
seven individuals (215 African American and 265 white
sibships). These sibships are among those participating
in the Hypertension Genetic Epidemiology Network
(HyperGEN) within the National Heart, Lung and
Blood Institute (NHLBI) Family Blood Pressure Pro-
gram, a study designed to identify genetic contributions
to hypertension (Williams et al., 2000). Probands were
characterized by an onset of hypertension at 60 years
of age and by the presence of at least one additional
hypertensive sibling who was willing to participate. Hy-
pertension was defined as systolic BP 140 or diastolic
BP 90 during at least two separate evaluations or as
receipt of treatment for hypertension. Volunteers with
type 1 diabetes or renal failure were excluded, to remove
potential secondary causes of hypertension. The mean
age of the sibships was 52 years in African Americans
and 61 years in whites. Subjects were recruited from
existing cohort studies or from the community at large
from the five field centers in HyperGEN (Birmingham;
Forsyth County, NC; Minneapolis; Salt Lake City; and
Framingham, MA). Birmingham recruited African
Americans exclusively; Forsyth County recruited ∼50%
African American and ∼50% whites; and Minnesota,
Utah, and Framingham recruited only whites. In addi-
tion, a random sample of unrelated individuals was
recruited from the same source population as the hy-
pertensive sibling population. These individuals were re-
cruited without regard to their hypertension status.
Phenotyping
Creatinine clearance, a ratio of urinary creatinine to
serum creatinine adjusted for urine volume and collec-
tion duration (Mauck et al. 1986), was used to assess
renal function. Creatinine clearance has been shown to
be an accurate measure of renal function (Giovannetti
and Barsotti 1991). Serum and urine creatinine were
measured by a thin-film adaptation of the amidohydro-
lase enzymatic method using the Vitros analyzer (John-
son & Johnson Clinical Diagnostics). From serum cre-
atinine measured on fasting blood samples collected in
the field center, and the measured urine creatinine and
total volume of participant-collected overnight urine
samples, creatinine clearance was calculated as usual,
using the participant-reported collection time according
to the following formula (Mauck et al. 1986):
CR #V 1440urine urineCR clearance p # ,(ml/min) CR Durationserum (min)
where CRurine is creatinine level in urine (mg/dl), CRserum
is creatinine level in serum (mg/100 ml), and Vurine is
volume of urine (ml). Subjects with collection times !6
hours (65 whites and 160 African Americans) were ex-
cluded from the analyses because of the potential in-
accuracy of the creatinine clearance values in individuals
with short collection times. To satisfy the assumption of
normality in the variance-components linkage analysis,
outlying creatinine clearance values 1244 ml/min were
excluded (21 African Americans). The Shapiro-Wilk test
of normality was applied to test for deviations from
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normality ( and for African Amer-Pp .3882 Pp .6170
icans and whites, respectively, for the creatinine clear-
ance residuals).
Genotyping
Genotyping was performed by the NHLBI Mamma-
lian Genotyping Service. (For additional information re-
garding the genotyping methods, see the Web site of the
Center for Medical Genetics, Marshfield Medical Re-
search Foundation.) The genome screen was performed
by means of an automated technique with the SCAnning
FlUorescence Detector (SCAFUD). The CooperativeHu-
man Linkage Center screening set 8, which includes 387
microsatellite markers approximately equally spaced
every 9 cM throughout the genome, was used. The av-
erage marker heterozygosity was .76. Analyses and as-
signment of the marker alleles were performed using
computerized algorithms. Marker incompatibilitieswere
tested using ASPEX, a likelihood-based method. Siblings
with incompatibilities were excluded from the linkage
analysis, and only full sibs were included in the analysis.
Linkage Analysis
We applied a variance-components model to sibships
to examine evidence for linkage of a quantitative trait
locus (QTL) for creatinine clearance. A multipoint anal-
ysis was performed using GENEHUNTER2 (Pratt et al.
2000), which estimates the amount of variance in a
quantitative trait that can be attributed to a QTL at that
position. Maximum-likelihood values for the mean trait
value, additive and dominant variance components for
the QTL, additive and dominance components for other
unlinked loci, and an environmental variance were es-
timated. To test the hypothesis that the genetic variance
due to the QTL equals zero, the likelihood from the
maximum-likelihood model (in which the observed var-
iances between siblings were determined as a function
of the inheritance vector at a given marker locus) was
compared with the likelihood of the model in which the
QTL-variance components were constrained to zero.
The difference between the two log likelihoods yielded
a LOD score that is similar to the classical LOD score
in linkage analysis.
To reduce the variability due to nongenetic and genetic
variation from other pathways (thereby potentially in-
creasing the signal-to-noise ratio of genetic variability
from major genes to total phenotypic variability), cre-
atinine clearance values were regressed on age, age2, lean
body mass, pulse rate, pulse pressure, hormone-replace-
ment therapy, educational status, and physical activity.
All of these covariates contribute to variation in renal
function or creatinine clearance, and each explained a
significant portion of the variation (significant parameter
estimate and/or increase in ) in creati-2P  .15 r  .01
nine clearance in one or more of the race-sex groups in
the random sample.
The significant covariates ( ) in the randomP  .15
sample–residual models are as follows, with their re-
spective P values in the given sex-race group: age P p
.01 (white women), P p .09 (African American men);
age2 Pp .02 (white women), Pp .06 (AfricanAmerican
men); lean body mass P p .0001 (white women and
white and African American men), P p .0004 (African
American women); pulse rate P p .15 (white women);
pulse pressure Pp .04 (African American women); hor-
mone-replacement therapy Pp .04 (white women); ed-
ucation P p .08 (African American men), and physical
activity P p .12 (African American men).
This comprehensive model was subsequently applied
to the race- and sex-specific hypertensive samples to cal-
culate the residual creatinine clearance values. Lean
body mass and muscle mass are related to the production
of creatinine, because creatinine is broken down during
muscle contraction, and, thus, is directly related to the
amount of creatinine in the blood available for filtration.
Both pulse rate and pulse pressure affect the amount of
blood passing through the kidneys. An increase in car-
diac output, of which pulse rate and pulse pressure are
key components, increases the GFR. Hormone-replace-
ment therapy, and estrogen in particular, may have ben-
eficial effects on endothelial function and BP, both of
which can alter GFR. Increased physical activity also
increases GFR. Education may appear to be influential
because it is a known surrogate for other environmental
factors such as diet, a known modifier of renal function.
Each of these variables captures some environmental
variation or some variation effected through other ge-
netic pathways related to creatinine clearance, thus re-
ducing the nongenetic sources of variation in our sample.
This fully adjusted model was compared with one in
which creatinine clearance was regressed only on age
and age2.
Residual phenotypes were created for sex and race
groups separately. Allele frequencies were estimated sep-
arately in African Americans and whites, using marker
allele frequencies derived from a randomly selected sub-
group (191 whites and 99 African Americans). Genome
scans were performed separately for African Americans
and whites.
Results
The distribution of sibship sizes is described in table 1.
The mean values of creatinine clearance in this sample
were 122.8 and 111.3 ml/min in African Americans and
118.4 and 96.2 ml/min in whites, for men and women,
respectively. White men had the longest duration of di-
agnosed hypertension (17.0 years, compared with 15.6
years in white women and 15.4 years in African Amer-
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Table 1
Distribution of Sibship Sizes
No. of Sibs African Americans Whites
2 185 178
3 24 63
4 6 17
5 0 5
6 0 1
7 0 1
Total 215 265
ican men and women. White men were also taking the
greatest number of antihypertensivemedications (40.1%
were taking two or more medications, compared with
31.6% of white women and 37.9% and 34.6% of Af-
rican American men and women, respectively). African
American women had an average body mass index
(BMI) of 33.7 kg/m2, compared with 30.2 for African
American men and 30.2 and 30.8 for white men and
women, respectively. A summary of phenotypic char-
acteristics is given in table 2. The narrow-sense herita-
bilities of the adjusted creatinine clearance measure-
ments, estimated in the genetic model within
GENEHUNTER2, were 17% in African Americans and
18% in whites.
We found six regions on three chromosomes in the
minimally and fully adjusted models (table 3, fig. 1) in
which the peak LOD score was 11.9. Our best evi-
dence for linkage to creatinine clearance was found,
using the fully adjusted model in African Americans,
on the long arm of chromosome 3 with a peak multi-
point LOD score of 3.61 at position 214.6 cM, which
localizes to the cytogenetic band 3q27; no comparable
peak was observed in the whites at this position. Using
the fully adjusted model, we observed an additional
locus at 57.9 cM on chromosome 3 (LOD p 1.78) in
African Americans.
Using the fully adjusted creatinine clearance model in
the white sample, we identified two loci, with maximum
LOD scores of 2.36 and 1.91, on the long arm of chro-
mosome 6 at positions 102.8 cM and 166.4 cM, re-
spectively. However, no similar peaks were observed in
the African Americans. Two additional loci were iden-
tified in the white population on chromosome 3 (LOD
p 2.16, 97.5 cM) and on chromosome 1 (LODp 1.91,
159.2 cM), with no similar peaks in African Americans.
When compared with the minimally adjusted residual
model (adjusted for age and age2 only) the peak LOD
positions remain fairly consistent, although there is
some change in the magnitude of the peak LOD scores
(table 3, fig. 1).
The breakdown of the variance-components esti-
mates from GENEHUNTER2 can be found in table 3.
There was a general trend toward higher LOD scores
having a higher proportion of the QTL variance attrib-
uted to dominance variance, with the two highest LOD
scores having all dominance and no additive variance
(LOD p 3.61 in African Americans, 93% dominance;
LOD p 3.36 in whites, 65% dominance).
A search of candidate-gene databases for genes con-
tained within the chromosomal region 3q27 (the region
of our best evidence for linkage) identified two candi-
date genes, EHHADH (which has been localized to
3q26.3-3q28) and ApoD (which has been localized to
3q27-3qter).
Discussion
These are the first data to offer evidence of genetic link-
age to creatinine clearance, an indicator of renal func-
tion, among hypertensive humans. Our data suggest that
these influential regions differ between ethnic groups or
are more easily detected in one ethnic group than the
other. This difference between ethnic groups may be a
result of the differing patterns of renal response to hy-
pertension, with African Americans exhibiting signifi-
cantly higher rates of hypertension-induced renal failure
(Rostand et al. 1982; Tierney et al. 1989; Blythe and
Maddux 1991) and faster progression of renal failure
(Tierney et al. 1989). Therefore, it is plausible that the
influential genetic regions would differ by ethnicity, as
reported here.
The comparison of the residual models in this analysis
is encouraging because the positions of the peak LOD
scores remain consistent between the twomodels within
the reported standard error of location estimates (Rob-
erts et al. 1999). This suggests that the analysis is robust
to varying adjustment strategies. One explanation for
the variability in the magnitude of the peak LOD scores
between the minimally and fully adjusted residual phe-
notype is that the additional adjustment altered the de-
tectable genetic signal at the various loci. Where the
peaks increased, the genetic signal may have been
enhanced because of the reduction of nongenetic vari-
ability in creatinine clearance. Where the peaks de-
creased, the genetic signal may have been reduced be-
cause of shared genetic variance between creatinine
clearance and one or more covariates. A second equally
likely explanation is that the variation in the magnitude
of the peak LOD scores is the result of statistical fluc-
tuations in the data and not of an increasing or de-
creasing genetic signal at the various loci.
Because only small sibships (mean sibship size of 2.5
and 2.2 in whites and African Americans, respectively)
were sampled, the variance-components estimates may
not be highly accurate. In the case of our highest LOD
score (LOD p 3.61 at 214.6 cM on chromosome 3 in
African Americans), all of the genetic variation is in the
dominance component (93% dominance, 0% additive).
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Table 2
Phenotypic and Other Characteristics of Study Participants
CHARACTERISTICa
AFRICAN AMERICANS WHITES
Men
(n p 124)
Women
(n p 342)
Men
(np 309)
Women
(n p 342)
Age (years) 52.8 (9.7) 51.5 (10.3) 60.9 (8.7) 61.3 (8.6)
Height (m) 1.75 (0.06) 1.63 (0.06) 1.75 (0.07) 1.62 (0.06)
Weight (lbs) 205.2 (43.6) 197.2 (48.5) 204.9 (37.6) 178.8 (41.1)
BMI (kg/m2) 30.2 (6.0) 33.7 (7.8) 30.2 (4.9) 30.8 (6.8)
Lean body mass (kg) 74.0 (7.1) 64.3 (0.4) 76.1 (6.3) 63.4 (6.1)
No. of anti-HT medications
0 15.3% 12.7% 7.4% 6.3%
1 46.8% 52.6% 52.5% 62.1%
2 30.6% 25.6% 30.8% 26.6%
3 7.3% 9.0% 9.3% 5.0%
Hormone replacement NA 37.5% NA 66.8%
SBP (mm Hg) 132.3 (21.5) 130.8 (22.3) 126.1 (19.2) 125.5 (19.1)
PP (mm Hg) 54.0 (15.5) 57.0 (17.5) 53.4 (14.8) 59.0 (16.3)
Pulse rate 70.0 (14.2) 72.9 (11.1) 66.4 (11.6) 70.3 (12.3)
HT duration (years) 15.4 (11.1) 15.4 (12.1) 17.0 (11.4) 15.6 (10.7)
CR clearance (ml/min) 122.8 (46.0) 111.3 (41.7) 118.4 (34.3) 96.2 (31.2)
Serum CR (mg/100ml) 1.20 (0.5) 0.96 (0.60) 1.10 (0.30) 0.89 (0.18)
Urine creatinine (mg/dl) 152.7 (77.1) 100.1 (59.0) 111.0 (52.4) 70.9 (41.0)
Education
!High school 34.7% 21.8% 9.4% 10.8%
High school 29.0% 28.6% 31.7% 50.0%
College 12.9% 16.9% 8.7% 10.8%
Postgraduate 23.4% 32.9% 50.2% 28.4%
Physical activity 2.3 (2.4) 2.4 (2.2) 2.6 (2.4) 2.1 (2.3)
NOTE.—All data are means (SD), except where noted. NA p not applicable.
a CRp creatinine; HTp hypertension. Physical activity indicates subject’s report of no. of times per
week when physical activity induced sweating. Postgraduate includes professional training.
In simulations in which a dominance-variance compo-
nent is included in the simulated trait and dominance
is modeled in GENEHUNTER2, there is an upward bias
of the dominance-variance component and a downward
bias of the additive variance component (Pratt et al.
2000). The present simulation was conducted using a
more informative pedigree structure, including cousins,
resulting in better estimates of variance components
than when small sibships are used. However, because
variation in creatinine clearance is probably influenced
by multiple genes, as well as by gene-gene and gene-
environment interactions, it is also plausible that the
dominance-variance component is absorbing some of this
genetic complexity, thereby inflating the estimate. This
may also explain why we were able to find such strong
linkages despite our modest heritability estimates.
Our search of available databases for candidate loci
revealed two candidate genes, in the 3q27 region, that
may be influential in determining renal function. The
peroxisomal bifunctional protein EHHADH is a mem-
ber of the peroxisomal b-oxidation pathway. EHHADH
has been shown to be expressed in the peroxisomes,
which are particularly abundant in both hepatocytes
and renal proximal epithelial cells, and has been local-
ized, using FISH, to chromosome 3q26.3-3q28 (Hoefler
et al. 1994). Patients with the G1528C mutation of 3-
hyroxyacyl-CoA dehydrogenase exhibit hepatomegaly
and steatosis of the liver, as well as accumulation of fat
in the myocardium, renal tubules, and skeletal muscle
(Tyni et al. 1997). Although this particular mutation is
often lethal before the age of two years, it suggests that
defects in the EHHADH gene could affect the renal
tubules and that a nonlethal mutation in this gene could
induce renal damage through the accumulation of long-
chain fatty acids in the renal tubules.
ApoD, the gene for which has been localized to 3q27-
3qter, is a human-protein component of plasma high-
density lipoprotein (Fielding and Fielding 1980; Albers
et al. 1981), but little is known about its function. It
has been hypothesized that ApoD may be involved in
the transport of cholesteryl esters to the liver for catab-
olism and in the efflux of cholesterol from peripheral
tissues (Drayna et al. 1987). A polymorphism in ApoD
has been associated with non–insulin-dependent dia-
betes mellitus (Baker et al. 1991, 1994) and, more re-
cently, with obesity and hyperinsulinemia (Vijayarag-
havan et al. 1994). ApoD has been shown to be
expressed in the kidney as well as in a host of other
tissues (Drayna et al. 1986). The possible role of ApoD
in renal damage is highly speculative, but it may act
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Table 3
Peak Multipoint LOD scores and QTL Variance-Components Estimates, by Race
Race and
Chromosome LOD Model
Position
(cM) Marker(s) (Position, cM) VP VA VD
African American
3 1.78 Full 57.9 D3S2432 (57.9) 1610.6 .0 (0%) 862.9 (54%)
3 2.50 Minimal 57.9 D3S2432 (57.9) 1856.0 .0 (0%) 1187.6 (64%)
3 3.61 Full 214.6 D3S2398 (209.4)/D3S2418 (215.8) 1610.6 .0 (0%) 1505.9 (93%)
3 2.31 Minimal 213.3 D3S2398 (209.4)/D3S2418 (215.8) 1856.0 290.3 (16%) 1162.2 (63%)
White
1 1.91 Full 159.2 D1S534 (151.9)/D1S1653 (164.1) 865.3 504.8 (58%) .0 (0%)
1 1.49 Minimal 169.5 D1S1653 (164.1)/D1S1679 (170.8) 995.8 170.0 (17%) 408.7 (41%)
3 2.16 Full 97.5 D3S4542 (89.9)/D3S2406 (102.6) 865.3 187.0 (22%) 389.4 (45%)
3 3.36 Minimal 115.1 D3S4529 (112.4)/D3S2459 (119.1) 995.8 .0 (0%) 643.2 (65%)
6 2.36 Full 102.8 D6S1056 (102.8) 865.3 .0 (0%) 473.2 (55%)
6 2.97 Minimal 112.2 D6S1021 (112.2) 995.8 9.0 (1%) 613.6 (62%)
6 1.91 Full 166.4 D6S305 (166.4) 865.3 394.7 (45%) 126.8 (15%)
6 1.47 Minimal 166.4 D6S305 (166.4) 995.8 424.2 (43%) .0 (0%)
NOTE.—For comparison, the LOD score is given for the nearest peak for the opposite residual model. The corresponding residual
model used to obtain the score is reported, either fully adjusted (age and age2, lean body mass, pulse rate, pulse pressure, hormone
replacement therapy, education status, and physical activity) or minimally adjusted (age, age2). The markers given are those either at
the peak LOD position or those that are flanking the position, if the peak LOD occurred between markers. For each marker, the
position, in centimorgans, is given in parentheses. Also reported are the variance components estimates from GENEHUNTER2 for
each peak position. VP p phenotypic variation, VA p additive variation, and VD p dominance variation.
through atherosclerosis in the renal blood vessels, al-
though no evidence exists to support this hypothesis.
One limitation of the present study is the inability to
infer the etiologic pathway between hypertension and
renal function and the role the linked regions play in
this pathway. There is evidence for kidney damage as
a cause (de Wardener 1990) and a consequence (Lin-
deman et al. 1984; Walker et al. 1992) of hypertension.
The present study recruited a population in which each
person was diagnosed with primary hypertension at
60 years of age. Although subjects diagnosed with
renal failure were excluded (to eliminate subjects with
renal failure–induced hypertension), it is still possible
that a decrease in renal function, although not consid-
ered renal failure, may be responsible for the increased
BP. At the same time, this decrease in renal function
may be the result of kidney damage induced by hyper-
tension. On the basis of the epidemiological evidence
of elevated rates of hypertension-induced renal failure
among African Americans, it is tempting to conclude
that in the African American study population the
linked region is a susceptibility locus for hypertension-
induced renal damage. Likewise, this may be a locus
that results in renal damage independent of hyperten-
sion and that consequently leads to elevated BP due to
renal damage.
Another potential limitation of the present study is
the use of creatinine clearance as a measure of renal
function. Creatinine clearance, although it does not di-
rectly measure the GFR, has been shown to be a good
estimate of the GFR and an accurate reflection of re-
ductions in GFR in both normal individuals and those
suffering from chronic renal failure (Giovannetti and
Barsotti 1991). Although a 24-h urine collection (i.e.,
24 h between first and last collection) is optimal in
determining creatinine clearance, collection times sig-
nificantly less than 24 hours accurately measure creat-
inine clearance; however, when short collection times
are used, measures of creatinine clearance begin to de-
viate substantially from the true rate (Baumann et al.
1987). Therefore, we eliminated all subjects with col-
lection times !6 h, to reduce the variability introduced
by inaccuracy in measurement of creatinine clearance
in these subjects. Nonetheless, measurement error may
have reduced the power to detect linkage.
Recently it has been noted that the LOD score from
a variance-components analysis that includes a domi-
nance parameter corresponds to a x2 test with 2 df in-
stead of the traditional 1 df, thereby increasing the re-
quirement for a genomewide significant LOD score
(Morton 1998). A genomewide significance level of .05
(nominal P value of .0001), which corresponds to a
LOD score of 3.3 in linkage analysis (the criterion sug-
gested by Lander and Kruglyak [1995] for “significant
linkage”), using a 1-df test corresponds to 3.7 using a
x2 test with 2 df.
Although our linkage results appear promising, it
should be noted that none of these linkages reach a
sufficiently high LOD score to be termed a “significant
linkage.” Furthermore, given our strategy of using mul-
tiple residual phenotypes and of stratifying by race, this
threshold would need to be further increased to account
for multiple testing. Therefore, all the linkages reported
here should be viewed as preliminary evidence for link-
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Figure 1 Results of the multipoint linkage analysis for African Americans (AA) and whites (W) for both the minimally adjusted and fully
adjusted residual creatinine-clearance models. Each scanned marker is given, along the x-axis, at its respective distance (in cM) from the
p-telomere (left) to the q-telomere (right), and the distance (in cM) of the last marker is given in parentheses.
age until further studies can confirm or refute the evi-
dence for linkage of creatinine clearance to these ge-
nomic regions.
In conclusion, we have found evidence for linkage to
creatinine clearance. Our best evidence of linkage is on
chromosome 3 at 214.6 cM (LOD p 3.61, fully ad-
justed) in African Americans. In addition, we found
weaker evidence of linkage to five regions. We identified
four loci in whites: one on chromosome 3 at 115.1 cM
(LOD p 3.36, minimally adjusted), two on chromo-
DeWan et al.: Genome Scan for Renal Function 143
some 6 at 112.2 cM (LODp 2.97, minimally adjusted)
and at 166.4 cM (LOD p 1.91, fully adjusted), and
one on chromosome 1 at 159.2 cM (LODp 1.91, fully
adjusted). An additional locus in African Americans on
chromosome 3 at 57.9 cM (LOD p 2.50, minimally
adjusted) was also localized. None of the observed
peaks were comparable between race groups. Positional
candidates in the most promising region on chromo-
some 3 include EHHADH and ApoD.
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